Merck Sharp & Dohme disclosed new benzimidazole derivatives that inhibit the NLRP3 inflammasome, expanding its disclosed chemistry around inflammasome modulation. The patent describes compounds potentially useful across a broad set of inflammatory conditions, including atherosclerosis, metabolic dysfunction-associated steatohepatitis (MASH), and neuroinflammatory diseases. NLRP3 inflammasome inhibitors are an active discovery area because inflammasome signaling contributes to downstream inflammatory cytokine pathways. While the patent disclosure does not by itself establish clinical outcomes, it can signal how MSD is continuing to develop and protect mechanisms in the NLRP3 space. The breadth of potential indications cited in the patent underscores a strategy to align inflammasome biology with multiple therapeutic areas as preclinical programs mature.